✦ LIBER ✦

New Efficient Asymmetric Synthesis of Taranabant, a CB1R Inverse Agonist for the Treatment of Obesity

✍ Scribed by Wallace, Debra J.; Campos, Kevin R.; Shultz, C. Scott; Klapars, Artis; Zewge, Daniel; Crump, Brian R.; Phenix, Brian D.; McWilliams, J. Christopher; Krska, Shane; Sun, Yongkui; Chen, Cheng-yi; Spindler, Felix

Book ID: 120938981
Publisher: American Chemical Society
Year: 2009
Tongue: English
Weight: 150 KB
Volume: 13
Category: Article
ISSN: 1083-6160
DOI: 10.1021/op800270e

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Catalytic, Enantioselective Synthesis of

Catalytic, Enantioselective Synthesis of Taranabant, a Novel, Acyclic Cannabinoid-1 Receptor Inverse Agonist for the Treatment of Obesity

✍ Chen, Cheng-yi; Frey, Lisa F.; Shultz, Scott; Wallace, Debra J.; Marcantonio, Ka 📂 Article 📅 2007 🏛 American Chemical Society 🌐 English ⚖ 180 KB

The Discovery of Taranabant, a Selective

The Discovery of Taranabant, a Selective Cannabinoid-1 Receptor Inverse Agonist for the Treatment of Obesity

✍ William K. Hagmann 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 817 KB

ChemInform Abstract: The Discovery of Ta

ChemInform Abstract: The Discovery of Taranabant, a Selective Cannabinoid-1 Receptor Inverse Agonist for the Treatment of Obesity

✍ William K. Hagmann 📂 Article 📅 2008 🏛 John Wiley and Sons ⚖ 23 KB 👁 2 views

## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable v

EFFECTS OF TARANABANT, A NOVEL CANNABINO

EFFECTS OF TARANABANT, A NOVEL CANNABINOID 1 RECEPTOR (CB-1R) INVERSE AGONIST, ON WEIGHT REDUCTION IN OBESE PATIENTS OVER 12 WEEKS

✍ Carr, R.; Erondu, N.; Gonzalez, C.; Gumbiner, B.; Musser, B.; Lu, K.; Capece, R. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 102 KB

A clinical trial assessing the safety an

A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study

✍ Proietto, J; Rissanen, A; Harp, J B; Erondu, N; Yu, Q; Suryawanshi, S; Jones, M 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 494 KB

A clinical trial assessing the safety an

A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study

✍ Aronne, L J; Tonstad, S; Moreno, M; Gantz, I; Erondu, N; Suryawanshi, S; Molony, 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 711 KB